» Articles » PMID: 29930715

Leinal Polypeptide Promotes NK Cells to Suppress PCa Survival

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Jun 23
PMID 29930715
Authors
Affiliations
Soon will be listed here.
Abstract

As an important component in the innate immune system, natural killer (NK) cells have been demonstrated to be clinically associated with prostate cancer (PCa) progression and castration resistance. Therefore, the development of novel agents that may enhance the cytotoxicity of NK cells possesses promising therapeutic applications. In the present study, leinal polypeptide (LP) solution was supplemented into a co-culture system of NK and PCa cells, as it was previously demonstrated that LP are able to activate NK cells, which kill PCa cells based on an MTT cell viability assay. Mechanistic dissection demonstrated that LP enhanced androgen receptor degradation, which resulted in an upregulation of MHC class I polypeptide-related sequence A (MICA) and MICB. In turn, the induced expression of MICA and MICB was able to further trigger NK cell activation, forming a positive loop between NK cells and PCa cells in the presence of LP solution.

References
1.
Huggins C . EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE. Ann Surg. 1942; 115(6):1192-200. PMC: 1543858. DOI: 10.1097/00000658-194206000-00030. View

2.
Lin S, Chou F, Li L, Lin C, Yeh S, Chang C . Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Lett. 2017; 398:62-69. DOI: 10.1016/j.canlet.2017.03.035. View

3.
Brett A, Pandey S, Fraizer G . The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells. Mol Cancer. 2013; 12:3. PMC: 3568020. DOI: 10.1186/1476-4598-12-3. View

4.
Guo Y, Hu Q, Sun C, Gu B, Xu K, Xia G . Postoperative renormalization of C-reactive protein with adjuvant lienal polypeptide and its association with tumour recurrence in T1 clear cell renal cell carcinoma. J Int Med Res. 2016; 44(3):620-6. PMC: 5536711. DOI: 10.1177/0300060515621640. View

5.
Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-97. DOI: 10.1056/NEJMoa1207506. View